Jinghua Pharmaceutical Group Co., Ltd.

Equities

002349

CNE100000L14

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-29 pm EDT 5-day change 1st Jan Change
7.88 CNY +0.13% Intraday chart for Jinghua Pharmaceutical Group Co., Ltd. +3.55% -11.16%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jinghua Pharmaceutical's Unit Shuts Down Amid Water Pollution Probe MT
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Jinghua Pharmaceutical Group Co., Ltd. Announces Cash Dividend for 2022, Payable on 9 June 2023 CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Jinghua Pharmaceutical Group Co., Ltd. Proposes Final Dividend for the Year 2022 CI
Jinghua Pharmaceutical Group Co., Ltd. Approves Cash Dividend for the Year 2022 CI
Jinghua Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for the Year 2022 CI
China COVID infection fears fuel medical stock bets RE
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Jinghua Pharmaceutical Group Co., Ltd.(XSEC:002349) added to S&P Global BMI Index CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Jinghua Pharmaceutical Group Co., Ltd. Implements 2021 Final Profit Distribution Plan (A Shares), Payable on 13 June 2022 CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Jinghua Pharmaceutical Group Co., Ltd. Approves Profit Distribution for 2021 CI
Jinghua Pharmaceutical's Controlling Shareholder Plans to Cut 2% Stake CI
Jinghua Pharmaceutical Group Co., Ltd. Proposes Final Dividend for 2021 CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Three Chinese Drugmakers Deny Receiving Orders From Pfizer MT
Nantong Jinghua Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Haian Ruihai Urbanization Investment and Construction Co., Ltd., completed the acquisition of 10.29% stake in Nantong Jinghua Pharmaceutical Co., Ltd. from Zan Shengda. CI
Jiangsu Qichen New Materials Co., Ltd. acquired 24.9% stake in Jiangsu Wannianchang Pharmaceutical Co., Ltd. from Nantong Jinghua Pharmaceutical Co., Ltd. for CNY 69.4 million. CI
Nantong Jinghua Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2021, Payable 17 September 2021 CI
Chart Jinghua Pharmaceutical Group Co., Ltd.
More charts
JINGHUA PHARMACEUTICAL GROUP CO., LTD., formerly NANTONG JINGHUA PHARMACEUTICAL CO., LTD., is a China-based company, principally engaged in the research and development, production and distribution of Chinese patent drugs, pharm ingredients and intermediates and chemical intermediates. The Company is also engaged in the provision of traditional Chinese medicinal materials and Chinese herbal pieces, among others. The Company primarily provides tablets, capsules, pills, granules, injections, powder, syrup, healthcare products, beverages and chemical intermediates, among others. The Company offers Chinese patent medicines, such as Wangshi Baochiwan pills and Jidesheng tablets. Its bulk drugs include phenobarbitone and fluorouracil. The Company distributes its products in domestic and overseas markets.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 002349 Stock
  4. News Jinghua Pharmaceutical Group Co., Ltd.
  5. Jinghua Pharmaceutical's Unit Shuts Down Amid Water Pollution Probe